EcoDrugPlus

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSNBRG00000021341
Gene Symbol: LOC102788561
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSNBRG00000008241
Gene Symbol: LOC102800292
3 Cross references
201 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSNBRG00000015096
Gene Symbol: LOC102783113
3 Cross references
202 Possible Orthologues:

Prostaglandin F2-Alpha Receptor-Like

Ensembl ID : ENSNBRG00000024234
Gene Symbol: LOC102779726
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSNBRG00000006683
Gene Symbol: LOC102786276
3 Cross references
182 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSNBRG00000012998
Gene Symbol: LOC102791634
2 Cross references
212 Possible Orthologues:

Prostaglandin G/h Synthase 2-Like

Ensembl ID : ENSNBRG00000020828
Gene Symbol: LOC102780434
3 Cross references
214 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSNBRG00000005586
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSNBRG00000019927
Gene Symbol: PSMA4
4 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSNBRG00000005191
Gene Symbol: PSMB11B
1 Cross references
159 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSNBRG00000003906
Gene Symbol: PSMD2
4 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSNBRG00000015701
Gene Symbol: PSMD4A
1 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).